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Purpose: Tenomodulin (TNMD) is located in the X-chromosome encoding a putative angiogenesis inhibitor which is
expressed in retina. Associations of single nucleotide polymorphisms of TNMD with the prevalence of age-related macular
degeneration (AMD) were examined.
Methods: Six markers covering 75% of the common sequence variation in the coding region of TNMD and 10 kb up- and
downstream were genotyped in a sample consisting of 89 men and 175 women with exudative AMD, 18 men and 25
women with atrophic AMD, and 55 men and 113 women without AMD. All participants were over 65 years old and did
not have diabetes mellitus. Due to the chromosomal locus, the association of genotypes with AMD was assessed
genderwise.
Results: Three markers, rs1155974, rs2073163, and rs7890586, were associated with a risk of AMD in women. In
comparison  to  women  with  other  genotypes,  the  women  who  were  homozygous  for  the  minor  allele  (genotypes
rs1155974-TT or rs2073163-CC) had 2.6 fold (p=0.021) or 1.9 fold (p=0.067) risk for having AMD, respectively. These
differences were due to the unequal prevalence of exudative AMD. In comparison to women who were homozygous for
the major alleles, the women with rs1155974-TT genotype had a 2.8 fold risk (p=0.021 in additive model; p=0.022 in
recessive model) for exudative AMD, and the women with rs2073163-CC genotype had a 1.8 fold risk (p=0.09 in additive
model; p=0.038 in recessive model). Furthermore, women carrying the rare rs7890586-AA genotype had a significantly
smaller risk for having AMD than women with the other genotypes (odds ratio 0.083; p=0.001 in recessive model), but
due to the low frequency of this genotype, this finding must be interpreted cautiously. The false discovery rate was <10%
for all of the aforementioned results.
Conclusions: On the basis of the putative antiangiogenic role of TNMD and the present genetic associations of TNMD
with AMD in women, we suggest that TNMD could be a novel candidate gene for AMD. These results should be confirmed
in further studies.
Furthermore,  an  association  between  the  LOC387715/
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Age-related macular degeneration (AMD) is the leading
cause  of  irreversible  visual  loss  in  the  elderly  [1].  It  is
attributable to degenerative tissue alterations occurring at the
interface between the neural retina and underlying choroid
[2,3]. AMD can be divided into atrophic and exudative forms.
The  atrophic  form  is  more  common  and  accounts  for
approximately 80% of AMD cases. However, the exudative
form accounts for the majority of advanced cases [4]. The
disease  etiology  is  multifactorial—i.e.,  in  addition  to  a
substantial genetic component [5], aging, smoking, high body
mass  index,  hypertension,  and  hypercholesterolemia
predispose to AMD [6–11]. Choroidal neovascularization and
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leakage from the blood vessels are diagnostic markers for
exudative AMD. Oxidative stress, ischemia, or inflammation
can induce proliferative processes in the choroidal endothelial
cells, which then evokes the growth of new blood vessels into
subretinal or retinal space [2,12]. A thickening, calcification,
and fragmentation of Bruch’s membrane may predispose to
the development of choroidal neovascular membranes. The
harmful new blood vessels that are diagnostic for exudative
AMD  grow  through  Bruch’s  membrane,  where  they  can
disrupt  the  membrane  and  leak  blood  or  fluid  into  the
subretinal  pigment  epithelial  space  [3,4].  This  can  evoke
damage  to  the  photoreceptor  layer  and  result  in  vision
abnormalities or even total loss of vision [3,4].
The importance of genetic risk factors, specifically of
those related to the complement system, has been highlighted
in several studies. An association has been observed between
the Y402H polymorphism (rs1061170) of the complement
factor  H  gene  and  AMD  in  several  populations  [13–19].
762HTRA1 locus and AMD in populations of different origin has
been  documented  [20–28].  One  common  polymorphism
(rs2230199) in the complement component 3 has also been
associated  with  AMD  [29,30].  Other  putative  candidates
include  genes  related  to  fatty  acid  metabolism,  such  as
apolipoprotein E [31,32], ATP-binding cassette, subfamily A,
member 4 [33,34], and elongation of very long chain fatty
acids-like 4 [18], but their roles in the pathogenesis of AMD
are controversial.
Since dysregulated neovascularization is involved in the
pathogenesis of AMD, the angiogenesis regulators represent
interesting candidate genes. Tenomodulin (TNMD) is a type
II  transmembrane  glycoprotein  containing  a  C-terminal
domain  with  homology  to  chondromodulin-I,  which  is  a
cartilage-derived angiogenesis inhibitor [35–37]. During the
late developmental phase of mouse embryo, TNMD mRNA is
expressed  in  the  tendon  of  extraocular  muscles,  cornea,
sensory retina, sclera, lens epithelial cells at the equator, and
in the differentiating secondary lens fiber cells [38]. TNMD
has  been  reported  to  inhibit  angiogenesis  by  hindering
endothelial proliferation and tube formation [38,39], but this
has not been confirmed in vivo since the TNMD-deficient
mice  did  not  exhibit  any  vascular  abnormalities  when
examined by oxygen-induced retinopathy [40]. Recent results
suggest  that  single  nucleotide  polymorphisms  (SNPs)  of
TNMD  are  associated  with  obesity,  disturbed  glucose
metabolism, and conversion from impaired glucose tolerance
to type 2 diabetes [41] as well as with elevated serum levels
of systemic immune mediators [42] and serum lipoproteins
[43].  Due  to  these  connections  with  vascularization,
inflammation, lipid metabolism, and obesity, TNMD is an
interesting  potential  new  candidate  gene  for  AMD.  In
addition,  the  diaphanous  2  Drosophila  homolog  gene
(DIAPH), located in the same cytogenetic band Xq-22, has
been linked to AMD in a study by Zheng et al. [44]. In the
present  study,  we  investigated  the  associations  of  TNMD
SNPs with AMD.
METHODS
Subjects:  The  study  population  consisted  of  475  Finnish
subjects (162 men, 313 women). A total of 89 men and 175
women had exudative AMD, and 18 men and 25 women had
atrophic AMD. Patients with choroidal neovascularization
attributable to AMD were given their diagnosis based on
fundus  photographs  and  fluorescein  angiography  in  the
Department of Ophthalmology of Kuopio University Hospital
or Helsinki University Hospital. The control group (no signs
of AMD in fundus photographs) consisted of 55 men and 113
women. All participants were over 65 years old and did not
have diabetes mellitus. The study was approved by the Ethics
Committee of the Helsinki University Eye and Ear Hospital
and the tenets of the Declaration of Helsinki were followed.
All participants signed an informed consent form. Eligibility
criteria  was  based  on  biomicroscopy  examination,  fundus
photographs  and  fluorescein  angiography  which  were
performed before the study. The blood samples were stored in
−80  °C  until  DNA  isolation.  DNA  was  extracted  from
peripheral blood leucocytes by salt precipitation.
Genotype analysis: Six markers covering 75% of the common
sequence variation with r2>0.8 in the coding region of TNMD
(15 kb) and 10 kb upstream and downstream from the coding
region (35 kb) were selected with the Tagger algorithm [45].
The markers rs2073163 and rs1155974, associated with an
increased  risk  of  type  2  diabetes  [41]  and  elevated
concentrations of serum acute phase reactants [42] in our
previous studies, were included in the selection procedure.
Genotyping  was  performed  with  TaqMan  Allelic
Discrimination  Assay  according  to  the  manufacturer’s
instructions  using  ABI  Prism  7000  sequence  detector
(Applied  Biosystems,  Foster  City,  CA).  The  genotyping
success  rate  was  98.5%  for  rs7890586,  99.6%  for
rs1204384,  and  100%  for  the  markers  rs11798018,
rs5966709,  rs2073163,  and  rs1155974.  The  error  rate  for
genotyping was calculated by repeating a subset of randomly
selected samples representing 6.3% of the study cohort. The
error rate was 0% for all markers.
Statistics:  Haploview  software  [46]  was  used  for  linkage
disequilibrium  (LD)  and  Hardy–Weinberg  equilibrium
analysis, and association studies were performed with SPSS
14.0 for Windows (SPSS, Chicago, IL). The association of the
TNMD SNPs with the prevalence of AMD was tested with
logistic  regression  analysis.  Due  to  the  X-chromosomal
location, a genderwise analysis was performed. In women, the
association with the prevalence of AMD was assessed with
additive, dominant (major allele homozygotes versus other
genotypes), and recessive (minor allele homozygotes versus
other  genotypes)  models.  The  genderwise  differences  in
minor allele frequencies (MAF) were assessed with the χ2-test.
Haplotype analyses were performed with Thesias 3.1 software
[47].  Correction  for  multiple  hypothesis  testing  was
performed  with  false  discovery  rate  using  Q-value  1.0
software. π0 was estimated with the bootstrap method using λ
range from 0 to 0.9 by 0.05 [48]. The false discovery rate for
each p-value <0.1 was reported as q.
RESULTS
All markers, except rs7890586 (p=0.002) were in Hardy–
Weinberg equilibrium. This exception was unlikely due to a
genotyping  error,  as  confirmed  by  genotyping  a  random
subsample of the study population. The pairwise LD pattern
and positions of the markers are presented in Figure 1. The
genderwise minor allele frequencies are shown in Table 1.
In women, the markers rs7890586 and rs1155974 were
associated with total prevalence (atrophic or exudative form)
of AMD, and a trend was observed with rs2073163. The odds
ratios (OR) of the heterozygous women were similar to those
observed among women who were major allele homozygotes
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763(data not shown). In contrast, the women homozygous for the
minor alleles had significantly different ORs for having AMD
than women with other genotypes. In comparison to women
with other genotypes, the women who were homozygous for
either of the minor alleles rs1155974-TT or rs2073163-CC,
had 2.6 fold or 1.9 fold risk for having AMD, respectively
(Appendix 1). In addition, women with the rare rs7890586-
AA genotype displayed a significantly smaller risk for having
AMD  than  the  women  with  the  other  genotypes  (odds
ratio=0.083, Appendix 1).
In more specific terms, these differences were due to the
unequal  prevalence  of  exudative  AMD  in  the  genotype
groups. The women with rs2073163-CC genotype had a 2.1
fold risk (p=0.038) for exudative AMD, and the women with
rs1155974-TT  genotype  had  a  2.6  fold  risk  (p=0.022)  in
comparison to the women with other genotypes of the same
markers (p values refer to the recessive model; Appendix 1).
The women with rs7890586-AA genotype had a significantly
smaller risk for AMD than women with rs7890586-TT or
rs7890586-TA  genotypes  (p=0.002;  recessive  model,
Appendix 1). The OR of heterozygous women did not differ
between  those  observed  among  the  women  who  were
homozygous for the major allele (Appendix 1). None of the
markers were associated with prevalence of AMD among men
(Table 2). The false discovery rate was less than 10% for all
of the abovementioned associations and less than 5%, apart
from  that  of  rs2073163  with  total  prevalence  of  AMD
(q=0.067).
Haplotype analyses were performed according to the two
LD-based  haploblocks,  one  consisting  of  rs11798018  and
rs5966709  and  the  other  involving  rs2073163  and
rs1155974.  Additional  analyses  were  performed  for
combinations of individual markers that were associated with
AMD (rs7890586, rs2073163 and rs1155974). The results of
haplotype analyses were in line with the results of single
marker analyses in women, but neither of these approaches
revealed  a  haplotype  that  would  explain  the  results
substantially better than the individual markers (Table 3).
Figure  1.  Location  of  the  selected
markers along the TNMD gene and their
pairwise linkage disequilibrium pattern,
indicated by D'- (upper) and r2-values
(lower). Two haploblocks, defined by
solid spine of linkage disequilibrium are
denoted  by  gray  shading.  The  first
haploblock  consists  of  markers
rs11798018  and  rs5966709,  and  the
second  consists  of  rs2073163  and
rs1155974.
TABLE 1. THE GENDERWISE MINOR ALLELE FREQUENCIES OF THE GENOTYPED MARKERS.
     Marker
(minor allele)
Minor allele frequencies
(Men)
Minor allele frequencies
          (Women) p
rs7890586 (A) 0.175 0.055 0.00007
rs11798018 (A) 0.395 0.386 0.869
rs5966709 (T) 0.383 0.197 0.0001
rs2073163 (C) 0.315 0.279 0.462
rs1155974 (T) 0.346 0.241 0.036
rs1204384 (T) 0.304 0.198 0.024
The minor allele frequencies (MAF) of rs11798018 and rs2073163   did not differ between the genders. A minor difference was
observed in the MAF of rs1204384 and rs1155974 while the MAF of rs7890586 and rs5966709 differed more significantly
between men and women. Markers rs7890586, rs2073163, and rs1155974 were associated with AMD in women.
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According to the results of the present study, genetic variation
in the TNMD gene is associated with the prevalence of AMD
in women. The genotypes rs2073163-CC and rs1155974-TT
that associated with a higher prevalence of exudative AMD
among women in the present study (Appendix 1), were linked
with higher serum concentrations of macrophage migration
inhibitory factor and chemokine, CC motif ligand 5 in women
[42]. The same markers were associated with higher serum
acute  phase  reactant  concentrations  among  men  [42].  In
addition, the rs7890586-AA genotype was associated with a
lower  prevalence  of  exudative  AMD  among  women
(Appendix 1), but due to the low frequency of this genotype
(16  out  of  313  women),  this  finding  must  be  interpreted
cautiously. We did not observe associations with atrophic
AMD, which was likely due to the small number of cases as
the main aim of the study was to detect genetic risk factors for
exudative  AMD.  In  addition  to  single-marker  analyses,
haplotype analyses was performed, but they did not provide
additional information (Appendix 1 and Table 3). This may
be because the distribution of haplotypes that contained the
individual risk alleles was almost identical to the individual
allele frequencies. Since there were some missing genotypes,
the number of people in the haplotype analysis was slightly
lower  than  in  the  single  marker  analyses.  This  may  also
account for the weaker associations observed in the haplotype
analyses.
The gender difference may arise from the genetic locus
(Xq-22).  The  expression  and  function  of  X-chromosomal
genes  differ  between  genders,  partially  because  of  the
TABLE 2. THE ASSOCIATIONS OF THE SELECTED MARKERS OF THE TNMD GENE WITH EXUDATIVE AMD IN MEN.
Marker Genotype
Number of cases/
controls
    OR
(95%CI) p
rs7890586 GG 78/41 1 (reference) 0.112
AA 11/12 0.482 (0.196–1.187)
rs11798018 CC 58/31 1 (reference) 0.292
AA 31/24 0.690 (0.347–1.374)
rs5966709 GG 57/31 1 (reference) 0.359
TT 32/24 0.725 (0.362–1.441)
rs2073163 TT 60/41 1 (reference) 0.365
CC 29/14 1.415 (0.668–3.001)
rs1155974 CC 60/36 1 (reference) 0.808
TT 29/19 0.916 (0.450–1.864)
rs1204384 AA 61/39 1 (reference) 0.84
TT 27/16 1.079 (0.516–2.256)
Abbreviations: odds ratio (OR); confidence interval (CI). None of the markers was associated with the prevalence of AMD in men.
TABLE 3. ASSOCIATIONS OF THE TNMD HAPLOTYPES WITH TOTAL AMD (EXUDATIVE AND ATROPHIC) AND EXUDATIVE AMD IN WOMEN.
Total AMD                                                  Exudative AMD
OR (95% CI)                          p                           OR (95% CI)                         p
Haploblock 1 rs11798018 rs5966709
A G 0.437
C T 0.329 0.821 (0.541- 1.244) 0.35 0.918 (0.618–1.365) 0.674
C G 0.23 0.921 (0.627–1.353) 0.681 0.853 (0.557–1.306) 0.465
Haploblock 2
rs2073163 rs1155974
T C 0.637
C T 0.287 1.411 (0.972–2.047) 0.319 1.431 (0.979–2.091) 0.064
Markers associated with AMD in women
rs7890586 rs2073163 rs1155974
G T C 0.513
G C T 0.288 1.318 (0.875–1.986) 0.187 1.330 (0.877–2.017) 0.18
A T C 0.084 0.487 (0.241–0.986) 0.046 0.475 (0.226–0.999) 0.05
Haploblocks 1 and 2 are defined on the basis of solid spine of LD. In addition, a 3-marker haplotype was constructed of those
markers that were associated with AMD in women. The haplotype analyses did not reveal a haplotype that would explain the
results substantially better than the single-marker analyses. Abbreviations: odds ratio (OR); confidence interval (CI).
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Markers                                              Frequencyvariation in gene dosages and the random inactivation of one
of the X-chromosomes in women [49]. Since the expression
levels of TNMD mRNA in the adipose tissue of women are
double that encountered in men [50], it seems that the TNMD
locus is able to escape the X-inactivation. The TNMD locus is
also  relatively  distant  from  the  X-inactivation  center.
Genomic  imprinting  can  also  result  in  different  gene
expression  levels,  since  women  are  normally  mosaic  for
maternal and paternal active X-chromosomes; men harbor
only the maternal X-chromosome and therefore express the
maternally inherited genes in that locus [51]. In addition, the
cellular  microenvironment  can  differ  between  men  and
women,  due  to  differences  in  hormone  levels  and  gene
expression [52]. However, we cannot rule out the possibility
that the study was underpowered to detect these associations
in men. The observed differences in proportions were smaller
than  0.1,  and  the  number  of  men  included  in  this  study
population was probably not high enough to detect differences
of this magnitude. The MAF distribution of rs2073163 was
similar  in  both  genders  and  therefore  the  association  of
rs2073163 with AMD does not result from the imbalance in
the  allele  distribution  between  men  and  women.  Gender
differences  were  observed  in  the  MAF  of  rs1155974  and
rs7890586. It is difficult to speculate whether the associations
of rs1155974 and rs7890586, which were observed in women,
result from gender differences in MAFs; differences of equal
magnitude were observed with two other markers (rs5966709
and rs1204384) that were not associated with the prevalence
of AMD.
In  vivo  experiments  in  mice  with  oxygen-induced
retinopathy have revealed that a lack of TNMD does not result
in abnormal angiogenesis or retinal neovascularization [40].
Since  the  regulation  of  angiogenesis  is  a  multifactorial
process,  it  is  possible  that  other  factors  might  have
compensated for the absence of TNMD. The age-associated
factors can also vary between species. In addition, mice lack
the normal macula and cones and therefore the regulation of
retinal neovascularization in that species might be different
from  that  in  the  human  eye.  In  exudative  AMD,
neovascularization is evoked by a proliferation of abnormal
choroidal blood vessels behind the retina. The multifactorial
etiology  of  vascular  dysregulation  in  AMD  is  not  fully
understood, but the expression levels of many stimulatory and
inhibitory regulators of neovascularization are known to be
altered during pathogenesis [12,53,54]. For example, vascular
endothelial growth factor (VEGF), is known to be involved in
choroidal neovascularization [54] and accordingly, VEGF-
blocking  compounds  are  emerging  as  highly  successful
treatments for exudative AMD [55–58]. This provides further
evidence for the importance of angiogenesis regulators in
AMD and supports the theory of a disrupted balance between
stimulators  and  inhibitors  of  neovascularization  in  the
pathogenesis of exudative AMD.
The  genetic  association  studies  on  the  role  of  VEGF
polymorphisms in exudative AMD have delivered conflicting
results [59–62], but interestingly, polymorphisms of the gene
encoding  antiangiogenic  pigment  epithelial  growth  factor
have been linked to AMD [63,64]. In relation to these previous
association  studies  with  angiogenesis  regulators,  the
associations  between  TNMD  sequence  variation  and
exudative AMD point to an interesting hypothesis on the
regulatory role of TNMD in choroidal neovascularization and
exudative AMD. It is important to note that the false discovery
rate  for  the  associations  observed  in  women  was  low,
suggesting that TNMD is a promising new candidate gene for
AMD. The same cytogenetic band has been linked to AMD
by  Zheng  et  al.,  who  also  reported  gender-specific
associations with the DIAPH2 [44]. Therefore, despite the
lack of a replication sample, our results are supported by the
findings of this previous study. We recognize the need for the
replication  of  these  findings  in  other  study  populations.
Functional  studies  are  needed  to  reveal  the  potential
mechanisms accounting for these associations.
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769Appendix 1. The association of TNMD SNPs with AMD in women.
The associations of the selected markers of the TNMD
gene with the prevalence of total (athropic or exudative) and
exudative  AMD  are  reported  according  to  additive  and
recessive (minor allele homozygotes versus other genotypes)
models. False discovery rate (q) is indicated only for p<0.1.
The  markers  rs7890586,  rs2073163,  and  rs155974  were
associated with total and exudative AMDTo access the data,
click or select the words “Appendix 1.” This will initiate the
download of a pdf that contains the file. False discovery rate q
is reported only for p<0.1. Abbreviations: odds ratio (OR);
confidence interval (CI).
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